目的 探討強(qiáng)筋健骨膠囊聯(lián)合依替膦酸二鈉片治療骨質(zhì)疏松癥的臨床療效。方法 選擇2018年1月-2019年3月周口市中心醫(yī)院收治的92例骨質(zhì)疏松癥患者為研究對(duì)象，將所有患者按隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各46例。對(duì)照組口服依替膦酸二鈉片，0.2 g/次，2次/d，連續(xù)治療2周后停藥11周，13周為1個(gè)療程，共治療2個(gè)周期。治療組在對(duì)照組治療的基礎(chǔ)上口服強(qiáng)筋健骨膠囊，1.2 g/次，2次/d，連續(xù)治療26周。觀察兩組的臨床療效，比較兩組的骨密度（BMD）、骨代謝指標(biāo)、關(guān)節(jié)功能指標(biāo)、疼痛程度。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.43%、93.48%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組全髖、腰椎、股骨頸的BMD均明顯升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組全髖、腰椎、股骨頸的BMD均明顯高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的Ⅰ型前膠原氨基末端肽（PINP）、Ⅰ型膠原C末端肽（β-CTX）、骨特異性堿性磷酸酶（BALP）水平均明顯降低，骨鈣素（BGP）水平明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組的PINP、β-CTX、BALP水平均明顯低于對(duì)照組，BGP水平明顯高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的Oswestry功能障礙指數(shù)（ODI）、視覺模擬評(píng)分法（VAS）評(píng)分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組的ODI指數(shù)、VAS評(píng)分均明顯低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 強(qiáng)筋健骨膠囊聯(lián)合依替膦酸二鈉片治療骨質(zhì)疏松癥具有較好的臨床療效，能提高患者的BMD，改善骨代謝指標(biāo)和關(guān)節(jié)功能，具有一定的臨床研究?jī)r(jià)值。

Objective To investigate the clinical effect of Qiangjin Jiangu Capsules combined with Etidronate Disodium Tablets in treatment of osteoporosis. Methods Patients (92 cases) with osteoporosis in Zhoukou Central Hospital from January 2018 to March 2019 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Etidronate Disodium Tablets, 0.2 g/time, twice daily. After 2 weeks of continuous treatment, the drug was stopped for 11 weeks, and 13 weeks as a course of treatment, then patients were treated for 2 courses. Patients in the treatment group were po administered with Qiangjin Jiangu Capsules on the basis of the control group, 1.2 g/time, twice daily, and were treated for 26 weeks. After treatment, the clinical efficacies were evaluated, and BMD, bone metabolism indexes, joint function, and degree of pain in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.43% and 93.48%, respectively, and there was difference between two groups (P < 0.05). After treatment, the BMD of total hip, lumbar spine, and femoral neck in the treatment group were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the BMD in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of PINP, β-CTX and BALP in two groups were significantly decreased, but the levels of BGP in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the levels of PINP, β-CTX and BALP in the treatment group were significantly lower than those in the control group, but the levels of BGP in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, ODI and VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the ODI and VAS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Qiangjin Jiangu Capsules combined with Etidronate Disodium Tablets has clinical curative effect in treatment of osteoporosis, can improve BMD, bone metabolism, and joint function, which has a certain clinical application value.

R977